微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 26.9% | 2.81% | 0.18% | 124/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 26.85% | 0.97% | 1.57% | 126/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 26.44% | -3.62% | 5.75% | 122/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 25% | 6.79% | -4.46% | 130/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 26.17% | 6.14% | -1.61% | 126/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 26.6% | 7.95% | -3.05% | 124/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 27.43% | 3.09% | 17.18% | 124/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 23.41% | -15.02% | -5.04% | 135/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 24.65% | -13.14% | 0.06% | 131/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 24.64% | -16.78% | -7.42% | 131/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 26.61% | -14.36% | -3.4% | 123/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 27.55% | -8.59% | -2.93% | 125/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 28.38% | -8.28% | -4.13% | 119/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 29.6% | -3.76% | -4.73% | 119/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 31.07% | 4.15% | 3.11% | 109/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 30.14% | -11.38% | -2.61% | 127/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 30.94% | 2% | 0.58% | 111/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 30.76% | -12.21% | 3.11% | 121/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 29.84% | 2% | -12.27% | 107/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 34.01% | 31.11% | -2.96% | 120/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 35.04% | 2% | 35.1% | 109/159 | 54.11% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-12-31 | 25.94% | 2% | 2% | 123/159 | -1222.98% | 微芯生物 | 95.14% | 行业排名> |